Cargando…

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

INTRODUCTION: Natalizumab, a therapy for relapsing–remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended interval dosing (EID) of natalizumab to reduce PML risk, desp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelle, Juliette, Briant, Anais R., Branger, Pierre, Derache, Nathalie, Arnaud, Charlotte, Lebrun-Frenay, Christine, Cohen, Mikael, Mondot, Lydiane, De Seze, Jerome, Bigaut, Kevin, Collongues, Nicolas, Kremer, Laurent, Ricard, Damien, Bompaire, Flavie, Ohlmann, Charlotte, Sallansonnet-Froment, Magali, Ciron, Jonathan, Biotti, Damien, Pignolet, Beatrice, Parienti, Jean-Jacques, Defer, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043118/ https://www.ncbi.nlm.nih.gov/pubmed/36763307 http://dx.doi.org/10.1007/s40120-023-00440-5

Ejemplares similares

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Inflammatory-like presentation of CADASIL: a diagnostic challenge
por: Collongues, Nicolas, et al.
Publicado: (2012)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Innovative multidimensional gait evaluation using IMU in multiple sclerosis: introducing the semiogram
por: Voisard, Cyril, et al.
Publicado: (2023)

Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection
por: Bigaut, K., et al.
Publicado: (2021)

Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy Presenting as Mild Encephalopathy with Reversible Splenium Lesion
por: Héraud, Charlotte, et al.
Publicado: (2021)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
por: Branger, Pierre, et al.
Publicado: (2016)

Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies: An Observational Study
por: Bigaut, Kévin, et al.
Publicado: (2021)

Subacute monomelic radiculoplexus neuropathy following Comirnaty© (Pfizer-BioNTech COVID-19) vaccination: A case report
por: Coly, M., et al.
Publicado: (2023)

Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD)
por: Bigaut, Kévin, et al.
Publicado: (2019)

Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
por: Dorcet, Guillaume, et al.
Publicado: (2022)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring
por: Khoy, Kathy, et al.
Publicado: (2020)

Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
por: Levraut, Michael, et al.
Publicado: (2022)

CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments
por: Bernard-Valnet, Raphael, et al.
Publicado: (2021)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

Kappa Free Light Chain Index Predicts Disease Course in Clinically and Radiologically Isolated Syndromes
por: Levraut, Michael, et al.
Publicado: (2023)

Cutaneous and Mixed Nerve Silent Period Recordings in Symptomatic Paroxysmal Kinesigenic Dyskinesia
por: Cogez, Julien, et al.
Publicado: (2016)

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Marburg Multiple Sclerosis Variant: Complete Remission with Very Early Administration of Mitoxantrone—A Case Report
por: Capet, Nicolas, et al.
Publicado: (2021)

Commentary
por: Biotti, Damien, et al.
Publicado: (2013)

Balance Impairment in Radiation Induced Leukoencephalopathy Patients Is Coupled With Altered Visual Attention in Natural Tasks
por: Bargiotas, Ioannis, et al.
Publicado: (2019)

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial
por: Defer, Gilles, et al.
Publicado: (2018)

Combination of attentional and spatial working memory deficits in Bálint–Holmes syndrome
por: Pisella, Laure, et al.
Publicado: (2015)

Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases
por: Renaudineau, Yves, et al.
Publicado: (2022)

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2019)

Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review
por: Levraut, Michaël, et al.
Publicado: (2019)

Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors
por: Terziev, Robert, et al.
Publicado: (2021)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
por: de Sèze, Jérôme, et al.
Publicado: (2023)

Covid-19, the pandemic war: Implication for neurologists
por: de Seze, J., et al.
Publicado: (2020)

Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study
por: Levraut, Michael, et al.
Publicado: (2022)

A Prospective Study of Patients with Brain MRI Showing Incidental T2 Hyperintensities Addressed as Multiple Sclerosis: a Lot of Work to do Before Treating
por: Lebrun, Christine, et al.
Publicado: (2014)

A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis
por: Lebrun, Christine, et al.
Publicado: (2017)

Bronchial Artery Angiographic Aspects of COVID-19
por: Chau, Yves, et al.
Publicado: (2022)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
por: Lebrun-Frénay, Christine, et al.
Publicado: (2021)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0oncgr0igvc4q0a5ipi3urcr9k